Replies to post #188 on Cardiol Therapeutics Inc (CRDL)

[MahinAgency]

NASDAQ: $CRDL Promising clinical progress: Ongoing Phase II trials for myocarditis and pericarditis, with major data expected November 2024

Time to Add $CRDL Big wave coming

[MahinAgency]

NASDAQ: $CRDL H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.

CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.